{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:19:11Z","timestamp":1783030751060,"version":"3.54.6"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015570","name":"Bloodwise","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omta.2026.201695","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:56:50Z","timestamp":1770944210000},"page":"201695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4901-5858","authenticated-orcid":false,"given":"Claire","family":"Roddie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Weng-Kit Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve A.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Abbasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Cadinanos-Garai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketki","family":"Vispute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Bosshard-Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mitsikakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedika","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir G.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Ensell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashma","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.V.","family":"Marzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Farzaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourredine","family":"Himoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhatullah","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilyana","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Lowdell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S.","family":"Peggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201695_bib1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201695_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201695_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201695_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201695_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201695_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12967-017-1160-5","article-title":"Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells","volume":"15","author":"Stroncek","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201695_bib7","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omta.2026.201695_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib9","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201695_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/cgt.2014.78","article-title":"Towards a commercial process for the manufacture of genetically modified T cells for therapy","volume":"22","author":"Kaiser","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omta.2026.201695_bib11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","article-title":"Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy","volume":"18","author":"Mock","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201695_bib12","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood.2025028790","article-title":"Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion","volume":"146","author":"Roddie","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/hyb.1984.3.305","article-title":"A Unique Human B Lymphocyte Antigen Defined by a Monoclonal Antibody","volume":"3","author":"Meeker","year":"1984","journal-title":"Hybridoma"},{"key":"10.1016\/j.omta.2026.201695_bib14","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib17","first-page":"3119","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.omta.2026.201695_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2019-124177","article-title":"Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England","volume":"134","author":"Kuhnl","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib19","first-page":"205","article-title":"Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.omta.2026.201695_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201695_bib21","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omta.2026.201695_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions","volume":"12","author":"Castella","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201695_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","article-title":"Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing","volume":"20","author":"Noaks","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201695_bib24","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201695_bib25","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood-2017-04-779983","article-title":"Equal opportunity CAR T cells","volume":"129","author":"Rouce","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omta.2026.201695_bib27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.omta.2026.201695_bib28","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1182\/blood-2021-146882","article-title":"Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2","volume":"138","author":"Zurko","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib29","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omta.2026.201695_bib30","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201695_bib31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201695_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1099\/0022-1317-82-5-1027","article-title":"The \u201ccleavage\u201d activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring \u201c2A-like\u201d sequences","volume":"82","author":"Donnelly","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omta.2026.201695_bib33","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201695_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201695_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CJI.0b013e31823569e2","article-title":"Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy","volume":"35","author":"Lugthart","year":"2012","journal-title":"J. Immunother."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:36:46Z","timestamp":1783028206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3117387X26000303"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201695","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of two manufacturing methods in the phase I COBALT study of CD19CAR T for LBCL","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201695"}}